Facebook Follow AMS on Linkedin Follow us on Twitter @amsCoolAgain

Prasterone (Intrarosa) for Dyspareunia

From the Medical Letter

The FDA has approved the steroid prasterone (Intrarosa – Endoceutics) for intravaginal treatment of postmenopausal women with moderate-to-severe dyspareunia due to vulvovaginal atrophy (VVA) (Table 1). Also called dehydroepiandrosterone (DHEA), prasterone is produced in the adrenal glands, gonads, and brain and converted intracellularly into active metabolites of estrogens and androgens. DHEA has been available over the counter for years as an oral dietary supplement claimed to benefit sexual, cardiovascular, and neuropsychiatric dysfunction.1- 3

See first page preview 

 

Prasterone approved

Reference

Prasterone (Intrarosa) for dyspareunia. Med Lett Drugs Ther. 2017 Sep 11;59(1529):149-150. https://jamanetwork.com/journals/jama/article-abstract/2658313

Content updated October 2017

 

Print Email

Search

Facebook Follow AMS on Linkedin Follow us on Twitter @amsCoolAgain